X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUVEN LIFE - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUVEN LIFE AUROBINDO PHARMA/
SUVEN LIFE
 
P/E (TTM) x 19.9 17.5 113.8% View Chart
P/BV x 3.7 3.5 106.4% View Chart
Dividend Yield % 0.3 0.7 51.6%  

Financials

 AUROBINDO PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
SUVEN LIFE
Mar-18
AUROBINDO PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs809251 322.6%   
Low Rs504155 325.2%   
Sales per share (Unadj.) Rs281.149.1 572.1%  
Earnings per share (Unadj.) Rs41.49.7 425.6%  
Cash flow per share (Unadj.) Rs50.911.4 446.6%  
Dividends per share (Unadj.) Rs2.501.50 166.7%  
Dividend yield (eoy) %0.40.7 51.5%  
Book value per share (Unadj.) Rs199.460.3 330.7%  
Shares outstanding (eoy) m585.88127.28 460.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.1 56.6%   
Avg P/E ratio x15.920.9 76.0%  
P/CF ratio (eoy) x12.917.8 72.4%  
Price / Book Value ratio x3.33.4 97.9%  
Dividend payout %6.015.4 39.2%   
Avg Mkt Cap Rs m384,63025,825 1,489.4%   
No. of employees `00017.31.1 1,616.8%   
Total wages/salary Rs m21,308613 3,477.8%   
Avg. sales/employee Rs Th9,500.75,832.6 162.9%   
Avg. wages/employee Rs Th1,229.4571.5 215.1%   
Avg. net profit/employee Rs Th1,397.91,153.8 121.2%   
INCOME DATA
Net Sales Rs m164,6666,253 2,633.6%  
Other income Rs m1,020233 438.2%   
Total revenues Rs m165,6866,485 2,554.8%   
Gross profit Rs m37,7181,982 1,903.2%  
Depreciation Rs m5,580213 2,618.3%   
Interest Rs m77746 1,678.6%   
Profit before tax Rs m32,3801,955 1,656.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183718 1,139.3%   
Profit after tax Rs m24,2291,237 1,958.9%  
Gross profit margin %22.931.7 72.3%  
Effective tax rate %25.336.7 68.8%   
Net profit margin %14.719.8 74.4%  
BALANCE SHEET DATA
Current assets Rs m121,8785,622 2,167.8%   
Current liabilities Rs m86,8061,168 7,434.6%   
Net working cap to sales %21.371.2 29.9%  
Current ratio x1.44.8 29.2%  
Inventory Days Days13081 159.5%  
Debtors Days Days6836 190.3%  
Net fixed assets Rs m81,0373,325 2,437.5%   
Share capital Rs m586127 460.3%   
"Free" reserves Rs m116,2187,547 1,540.0%   
Net worth Rs m116,8047,674 1,522.1%   
Long term debt Rs m4,51214 32,460.4%   
Total assets Rs m211,0529,135 2,310.3%  
Interest coverage x42.743.2 98.7%   
Debt to equity ratio x00 2,132.7%  
Sales to assets ratio x0.80.7 114.0%   
Return on assets %11.814.0 84.4%  
Return on equity %20.716.1 128.7%  
Return on capital %27.426.0 105.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7275,066 1,593.5%   
Fx outflow Rs m34,7002,001 1,734.0%   
Net fx Rs m46,0273,065 1,501.7%   
CASH FLOW
From Operations Rs m19,548699 2,795.0%  
From Investments Rs m-19,570-6 320,811.5%  
From Financial Activity Rs m8,642-577 -1,497.7%  
Net Cashflow Rs m8,922116 7,671.6%  

Share Holding

Indian Promoters % 54.1 63.4 85.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 36.5 27.9%  
Shareholders   69,601 37,287 186.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS